Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin

Shiro Hinotsu, Hideyuki Akaza, Shigeo Isaka, Susumu Kagawa, Kenkichi Koiso, Toshihiko Kotake, Toyohei Machida, Yosuke Matsumura, Tadao Niijima, Koji Obata, Yasuo Ohashi, Hiroshi Ohe, Jun Shimazaki, Kazuya Tashiro

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A total of 465 patients with primary and multiple or recurrent, stages Ta and T1 superficial bladder cancer were included in this randomized multicenter trial to compare the prophylactic effect by 17 times instillation of 40 mg doxorubicin or 40 mg epirubicin with no instillation after transurethral resection of tumor(s). The primary endpoint was first recurrence after transurethral resection. Endoscopic examination as well as urinary cytology was performed in each case every three months. It became evident that the recurrence rate in the doxorubicin or epirubicin instillation arm was lower that in the no instillation arm. Toxicity was mainly restricted to bladder irritation in about 10% of patients in each instillation arm.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume29
Issue number1
Publication statusPublished - Jan 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin'. Together they form a unique fingerprint.

  • Cite this

    Hinotsu, S., Akaza, H., Isaka, S., Kagawa, S., Koiso, K., Kotake, T., Machida, T., Matsumura, Y., Niijima, T., Obata, K., Ohashi, Y., Ohe, H., Shimazaki, J., & Tashiro, K. (2002). Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin. Gan to kagaku ryoho. Cancer & chemotherapy, 29(1), 73-80.